This Phase 4 open-label trial evaluated real-world effectiveness of the antidepressant vortioxetine on the ability of patients with MDD to achieve pre-identified treatment goals.
Patients with MDD, requiring a switch in antidepressant treatment for inadequate response or tolerability issues, were given flexible dose vortioxetine (10-20 mg) for 12 weeks. Achievement of pre-identified treatment goals (primary outcome) was indicated by a GAS-D score of ≥50 at week 12. Total GAS-D scores, patient- and clinician-reported outcome measures, response/remission rates, and safety were also assessed.
Approximately 86% of enrolled patients (106/123) completed treatment—mean age 45 years, 82.8% women, and 69.2% white. A GAS-D score of ≥50 at week 12 was achieved by 57.8% of patients, with significant changes from baseline in total score (p<0.001). Significant improvements (p<0.001) were observed in depression severity (PHQ-9), cognitive functioning and performance (PDQ-D, DSST), well-being (WHO-5), and clinical global impression of severity (CGI-S). Numerical improvement was observed on assessments of functional capacity (VRFCAT) and clinical impression of improvement (CGI-I). Treatment response (≥50% total score reduction on PHQ-9) was reported by 64.2% of patients and remission (PHQ-9 ≤4) by 38.7%. Most adverse events were mild to moderately severe, consistent with product labeling.
A majority of patients treated with vortioxetine achieved their personalized treatment goals at week 12. Patients who switched to vortioxetine also experienced significant improvements in traditional patient- and clinician-reported assessments.
Clinical outcomes are presented here; the functional impact to patients and health outcomes results are presented in a separate abstract.